AMENDMENTS TO THE CLAIMS

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. **(original):** An antidepressant comprising, as an active ingredient, a compound having an antagonistic effect on group II metabotropic glutamate receptors.

2. **(currently amended):** A 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative of Formula [I]:




[I]

[wherein

$R^1$ and $R^2$, which may be the same or different, each represent a hydroxyl group, a $C_{1-10}$ alkoxy group, a phenoxy group, a naphthyloxy group, a $C_{1-6}$ alkoxy group which is substituted with one or two phenyl groups, a $C_{1-6}$ alkoxy-$C_{1-6}$ alkoxy group, a hydroxy-$C_{2-6}$ alkoxy group, an amino group, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkyl groups, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkoxy-$C_{1-6}$ alkyl groups, an amino group which is substituted with the same or different one or two hydroxy-$C_{2-6}$ alkyl groups, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkoxycarbonyl-$C_{1-6}$ alkyl groups, or a native or non-native amino acid residue

represented by $NR^6$-$CHR^7$-A-$CO_2R^8$ (wherein $R^6$ and $R^7$, which may be the same or different, each represent a hydrogen atom, a hydroxy-$C_{1-6}$ alkyl group, a hydroxycarbonyl-$C_{1-6}$ alkyl group, a $C_{1-10}$ alkyl group, a phenyl group, a phenyl-$C_{1-6}$ alkyl group, a hydroxyphenyl group, a hydroxyphenyl-$C_{1-6}$ alkyl group, a naphthyl group, a naphthyl-$C_{1-6}$ alkyl group, an aromatic heterocyclic $C_{1-6}$ alkyl group, a $C_{1-6}$ alkoxy-$C_{1-6}$ alkyl group, an amino-$C_{2-6}$ alkyl group, a guanidino-$C_{2-6}$ alkyl group, a mercapto-$C_{2-6}$ alkyl group, a $C_{1-6}$ alkylthio-$C_{1-6}$ alkyl group or an aminocarbonyl-$C_{1-6}$ alkyl group, or $R^6$ and $R^7$ may together represent a group capable of forming a methylene group, an ethylene group or a propylene group, or may together form a cyclic amino group; $R^8$ represents a hydrogen atom or a protecting group for a carboxyl group; and A represents a single bond, a methylene group, an ethylene group or a propylene group);

$R^3$ represents a hydrogen atom, a $C_{1-10}$ acyl group, a $C_{1-6}$ alkoxy-$C_{1-6}$ acyl group, a hydroxy-$C_{2-10}$ acyl group, a $C_{1-6}$ alkoxycarbonyl-$C_{1-6}$ acyl group, a hydroxycarbonyl-$C_{1-6}$ acyl group, or an amino acid residue represented by $R^9$-NH-A-$CHR^7$-CO (wherein $R^7$ and A are as defined above, and $R^9$ represents a hydrogen atom or a protecting group for an amino group); and

$R^4$ and $R^5$, which may be the same or different, each represent a hydrogen atom, a $C_{1-10}$ alkyl group, a $C_{2-10}$ alkenyl group, a phenyl group, a naphthyl group, a 5-membered heteroaromatic ring containing one or more heteroatoms, or a phenyl group substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, a $C_{1-10}$ alkyl group, a $C_{1-10}$ alkoxy group, a trifluoromethyl group, a phenyl group, a hydroxycarbonyl group, an amino group, a nitro group, a cyano group and a phenoxy group, or $R^4$ and $R^5$ may together form a cyclic structure]

or a pharmaceutically acceptable salt or hydrate thereof.

**3. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in Formula [I], $R^1$ and $R^2$ are each a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**4. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in Formula [I], $R^1$ is a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**5. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in Formula [I], $R^2$ is a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**6. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 2, wherein in Formula [I], $R^1$ and $R^2$ are each a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof.

**7. (currently amended):** A 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative of Formula [II]:




[II]

[wherein

$R^1$ and $R^2$, which may be the same or different, each represent a hydroxyl group, a $C_{1-10}$ alkoxy group, a phenoxy group, a naphthyloxy group, a $C_{1-6}$ alkoxy group which is substituted with one or two phenyl groups, a $C_{1-6}$ alkoxy-$C_{1-6}$ alkoxy group, a hydroxy-$C_{2-6}$ alkoxy group, an amino group, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkyl groups, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkoxy-$C_{1-6}$ alkyl groups, an amino group which is substituted with the same or different one or two hydroxy-$C_{2-6}$ alkyl groups, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkoxycarbonyl-$C_{1-6}$ alkyl groups, or a native or non-native amino acid residue represented by $NR^6$-$CHR^7$-A-$CO_2R^8$ (wherein $R^6$ and $R^7$, which may be the same or different, each represent a hydrogen atom, a hydroxy-$C_{1-6}$ alkyl group, a hydroxycarbonyl-$C_{1-6}$ alkyl group, a $C_{1-10}$ alkyl group, a phenyl group, a phenyl-$C_{1-6}$ alkyl group, a hydroxyphenyl group, a hydroxyphenyl-$C_{1-6}$ alkyl group, a naphthyl group, a naphthyl-$C_{1-6}$ alkyl group, an aromatic heterocyclic $C_{1-6}$ alkyl group, a $C_{1-6}$ alkoxy-$C_{1-6}$ alkyl group, an amino-$C_{2-6}$ alkyl group, a guanidino-$C_{2-6}$ alkyl group, a mercapto-$C_{2-6}$ alkyl group, a $C_{1-6}$ alkylthio-$C_{1-6}$ alkyl group or an aminocarbonyl-$C_{1-6}$ alkyl group, or $R^6$ and $R^7$ may together represent a group capable of forming a methylene group, an ethylene group or a propylene group, or may together form a cyclic amino group; $R^8$ represents a hydrogen atom or a protecting group for a carboxyl group; and A represents a single bond, a methylene group, an ethylene group or a propylene group);

$R^3$ represents a hydrogen atom, a $C_{1-10}$ acyl group, a $C_{1-6}$ alkoxy-$C_{1-6}$ acyl group, a hydroxy-$C_{2-10}$ acyl group, a $C_{1-6}$ alkoxycarbonyl-$C_{1-6}$ acyl group, a hydroxycarbonyl-$C_{1-6}$ acyl group, or an amino acid residue represented by $R^9$-NH-A-$CHR^7$-CO (wherein $R^7$ and A are as

defined above, and $R^9$ represents a hydrogen atom or a protecting group for an amino group); and

$R^4$ and $R^5$, which may be the same or different, each represent a hydrogen atom, a $C_{1-10}$ alkyl group, a $C_{2-10}$ alkenyl group, a phenyl group, a naphthyl group, a 5-membered heteroaromatic ring containing one or more heteroatoms, or a phenyl group substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, a $C_{1-10}$ alkyl group, a $C_{1-10}$ alkoxy group, a trifluoromethyl group, a phenyl group, a hydroxycarbonyl group, an amino group, a nitro group, a cyano group and a phenoxy group, or $R^4$ and $R^5$ may together form a cyclic structure]

or a pharmaceutically acceptable salt or hydrate thereof.

**8. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^1$ and $R^2$ are each a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**9. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^1$ is a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**10. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^1$ is a hydroxyl group, $R^3$ is a hydrogen atom, and $R^2$ is a $C_{1-10}$ alkoxy group or a $C_{1-6}$ alkoxy group substituted with one phenyl group, or a pharmaceutically acceptable salt or hydrate thereof.

**11. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^1$ is a hydroxyl group, $R^3$ is a hydrogen atom, and $R^2$ is NH-CHR$^7$-$CO_2H$, or a pharmaceutically acceptable salt or hydrate thereof.

**12. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^2$ is a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**13. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^2$ is a hydroxyl group, $R^3$ is a hydrogen atom, and $R^1$ is a $C_{1-10}$ alkoxy group or a $C_{1-6}$ alkoxy group substituted with one phenyl group, or a pharmaceutically acceptable salt or hydrate thereof.

**14. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^2$ is a hydroxyl group, $R^3$ is a hydrogen atom, and $R^1$ is NH-CHR$^7$-$CO_2H$, or a pharmaceutically acceptable salt or hydrate thereof.

**15. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^1$ and $R^2$ are each a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof.

**16. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 7, wherein in Formula [II], $R^1$ and $R^2$ are each a hydroxyl group and $R^3$ is $H_2N$-CHR$^7$-CO, or a pharmaceutically acceptable salt or hydrate thereof.

**17. (currently amended):** A 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative of Formula [III]:



[III]

[wherein

$R^1$ and $R^2$, which may be the same or different, each represent a hydroxyl group, a $C_{1-10}$ alkoxy group, a phenoxy group, a naphthyloxy group, a $C_{1-6}$ alkoxy group which is substituted with one or two phenyl groups, a $C_{1-6}$ alkoxy-$C_{1-6}$ alkoxy group, a hydroxy-$C_{2-6}$ alkoxy group, an amino group, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkyl groups, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkoxy-$C_{1-6}$ alkyl groups, an amino group which is substituted with the same or different one or two hydroxy-$C_{2-6}$ alkyl groups, an amino group which is substituted with the same or different one or two $C_{1-6}$ alkoxycarbonyl-$C_{1-6}$ alkyl groups, or a native or non-native amino acid residue represented by $NR^6$-$CHR^7$-A-$CO_2R^8$ (wherein $R^6$ and $R^7$, which may be the same or different, each represent a hydrogen atom, a hydroxy-$C_{1-6}$ alkyl group, a hydroxycarbonyl-$C_{1-6}$ alkyl group, a $C_{1-10}$ alkyl group, a phenyl group, a phenyl-$C_{1-6}$ alkyl group, a hydroxyphenyl group, a hydroxyphenyl-$C_{1-6}$ alkyl group, a naphthyl group, a naphthyl-$C_{1-6}$ alkyl group, an aromatic heterocyclic $C_{1-6}$ alkyl group, a $C_{1-6}$ alkoxy-$C_{1-6}$ alkyl group, an amino-$C_{2-6}$ alkyl group, a guanidino-$C_{2-6}$ alkyl group, a mercapto-$C_{2-6}$ alkyl group, a $C_{1-6}$ alkylthio-$C_{1-6}$ alkyl group or an

aminocarbonyl-$C_{1-6}$ alkyl group, or $R^6$ and $R^7$ may together represent a group capable of forming a methylene group, an ethylene group or a propylene group, or may together form a cyclic amino group; $R^8$ represents a hydrogen atom or a protecting group for a carboxyl group; and A represents a single bond, a methylene group, an ethylene group or a propylene group);

$R^3$ represents a hydrogen atom, a $C_{1-10}$ acyl group, a $C_{1-6}$ alkoxy-$C_{1-6}$ acyl group, a hydroxy-$C_{2-10}$ acyl group, a $C_{1-6}$ alkoxycarbonyl-$C_{1-6}$ acyl group, a hydroxycarbonyl-$C_{1-6}$ acyl group, or an amino acid residue represented by $R^9$-NH-A-CH$R^7$-CO (wherein $R^7$ and A are as defined above, and $R^9$ represents a hydrogen atom or a protecting group for an amino group); and

$R^4$ and $R^5$, which may be the same or different, each represent a hydrogen atom, a $C_{1-10}$ alkyl group, a $C_{2-10}$ alkenyl group, a phenyl group, a naphthyl group, a 5-membered heteroaromatic ring containing one or more heteroatoms, or a phenyl group substituted with 1 to 5 substituents selected from the group consisting of a halogen atom, a $C_{1-10}$ alkyl group, a $C_{1-10}$ alkoxy group, a trifluoromethyl group, a phenyl group, a hydroxycarbonyl group, an amino group, a nitro group, a cyano group and a phenoxy group, or $R^4$ and $R^5$ may together form a cyclic structure]

or a pharmaceutically acceptable salt or hydrate thereof.

**18. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^1$ and $R^2$ are each a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**19. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^1$ is a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**20. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^1$ is a hydroxyl group, $R^3$ is a hydrogen atom, and $R^2$ is a $C_{1-10}$ alkoxy group or a $C_{1-6}$ alkoxy group substituted with one phenyl group, or a pharmaceutically acceptable salt or hydrate thereof.

**21. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^1$ is a hydroxyl group, $R^3$ is a hydrogen atom, and $R^2$ is NH-CHR$^7$-$CO_2H$, or a pharmaceutically acceptable salt or hydrate thereof.

**22. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^2$ is a hydroxyl group and $R^3$ is a hydrogen atom, or a pharmaceutically acceptable salt or hydrate thereof.

**23. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^2$ is a hydroxyl group, $R^3$ is a hydrogen atom, and $R^1$ is a $C_{1-10}$ alkoxy group or a $C_{1-6}$ alkoxy group substituted with one phenyl group, or a pharmaceutically acceptable salt or hydrate thereof.

**24. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^2$ is a hydroxyl group, $R^3$ is a hydrogen atom, and $R^1$ is HN-CHR$^7$-$CO_2H$, or a pharmaceutically acceptable salt or hydrate thereof.

**25. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^1$ and $R^2$ are each a hydroxyl group, or a pharmaceutically acceptable salt or hydrate thereof.

**26. (original):** The 2-amino-3-alkoxy-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative according to claim 17, wherein in Formula [III], $R^1$ and $R^2$ are each a hydroxyl group and $R^3$ is $NH_2$-$CHR^7$-CO, or a pharmaceutically acceptable salt or hydrate thereof.

**27. (original):** A pharmaceutical preparation comprising one or more pharmaceutically acceptable carriers, excipients or diluents and the compound according to any one of claims 2 to 26.

**28. (original):** A drug comprising the compound according to any one of claims 2 to 26 as an active ingredient.

**29. (original):** The drug according to claim 28, which is an antagonist of group II metabotropic glutamate receptors.

**30. (original):** The use of the compound according to any one of claims 2 to 26 as a drug.